YS Biopharma
Signal active
Organization
Contact Information
Overview
YS Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.
About
Industries
Biotechnology, Health Care, Biopharma
Founded
2002
Employees
501-1000
Headquarters locations
Asia
Social
N/A
Profile Resume
YS Biopharma headquartered in Asia, operates in the Biotechnology, Health Care, Biopharma sector. The company focuses on Biotechnology and has secured $12.6B in funding across 60 round(s). With a team of 501-1000 employees, YS Biopharma is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - YS Biopharma, raised $40.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
5
Investors
0
Lead Investors
0
Total Funding Amount
$210.7M
Details
1
YS Biopharma has raised a total of $210.7M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 130.0M |
Investors
YS Biopharma is funded by 22 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| C-Bridge Capital | - | FUNDING ROUND - C-Bridge Capital | 40.0M |
| Yi Zhang | - | FUNDING ROUND - Yi Zhang | 671.5K |
| YS Biopharma | - | FUNDING ROUND - YS Biopharma | 671.5K |
| David (Hui) Shao | - | FUNDING ROUND - David (Hui) Shao | 671.5K |
Recent Activity
There is no recent news or activity for this profile.